Clinical Trial

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-11.
Trial Details
NCT Number NCT07652047
Lead Sponsor Corxel Pharmaceuticals
Conditions Obesity & Overweight
Enrollment 90 participants
Start Date 2026-05-11
Primary Completion 2027-03 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-17